1. Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66(1):7–30

2. Lowenfels AB, Maisonneuve P (2004) Epidemiology and prevention of pancreatic cancer. Jpn J Clin Oncol 34(5):238–244

3. Shaib Y, Davila J, El-Serag H (2006) The epidemiology of pancreatic cancer in the United States: changes below the surface. Aliment Pharmacol Ther 24(1):87–94

4. Bracci PM (2012) Obesity and pancreatic cancer: overview of epidemiologic evidence and biologic mechanisms. Mol Carcinog 51(1):53–63

5. Food N (2007) Physical activity, and the prevention of cancer: a global perspective. Washington, DC

6. Cowey S, Hardy RW (2006) The metabolic syndrome: a high-risk state for cancer? Am J Pathol 169(5):1505–1522

7. Włodarek D, Jerzy Podleśny JS (2007) Nonalcoholic fatty liver disease as a feature of the metabolic syndrome. Roczniki Państwowego Zakładu 58(1):129

8. Bechmann LP, Hannivoort RA, Gerken G, Hotamisligil GS, Trauner M, Canbay A (2012) The interaction of hepatic lipid and glucose metabolism in liver diseases. J Hepatol 56(4):952–964

9. Machado M, Cortez-Pinto H (2006) Non-alcoholic steatohepatitis and metabolic syndrome. Curr Opin Clin Nutr Metab Care 9(5):637–642

10. Pitt HA (2007) Hepato-pancreato-biliary fat: the good, the bad and the ugly. HPB 9(2):92–97

11. Targher G, Rossi A, Zamboni G, Fantin F, Antonioli A, Corzato F et al (2012) Pancreatic fat accumulation and its relationship with liver fat content and other fat depots in obese individuals. J Endocrinol Investig 35(8):748

12. Smits MM, van Geenen EJ (2011) The clinical significance of pancreatic steatosis. Nat Rev Gastroenterol Hepatol 8(3):169–177

13. Mathur A, Zyromski NJ, Pitt HA, Al-Azzawi H, Walker JJ, Saxena R et al (2009) Pancreatic steatosis promotes dissemination and lethality of pancreatic cancer. J Am Coll Surg 208(5):989–994

14. Sanna C, Rosso C, Marietti M, Bugianesi E (2016) Non-alcoholic fatty liver disease and extra-hepatic cancers. Int J Mol Sci 17(5):717

15. Saba L, di Martino M, Bosco S, del Monte M, de Cecco CN, Lombardo V et al (2015) MDCT classification of steatotic liver: a multicentric analysis. Eur J Gastroenterol Hepatol 27(3):290–297

16. Boyce CJ, Pickhardt PJ, Kim DH, Taylor AJ, Winter TC, Bruce RJ et al (2010) Hepatic steatosis (fatty liver disease) in asymptomatic adults identified by unenhanced low-dose CT. AJR Am J Roentgenol 194(3):623–628

17. Park YS, Park SH, Lee SS, Kim DY, Shin YM, Lee W et al (2011) Biopsy-proven nonsteatotic liver in adults: estimation of reference range for difference in attenuation between the liver and the spleen at nonenhanced CT. Radiology 258(3):760–766

18. Li D, Morris JS, Liu J, Hassan MM, Day RS, Bondy ML et al (2009) Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. JAMA 301(24):2553–2562

19. Balentine CJ, Enriquez J, Fisher W, Hodges S, Bansal V, Sansgiry S et al (2010) Intra-abdominal fat predicts survival in pancreatic cancer. J Gastrointest Surg 14(11):1832–1837

20. McWilliams RR, Matsumoto ME, Burch PA, Kim GP, Halfdanarson TR, De Andrade M et al (2010) Obesity adversely affects survival in pancreatic cancer patients. Cancer 116(21):5054–5062

21. Olson SH, Chou JF, Ludwig E, O’Reilly E, Allen PJ, Jarnagin WR et al (2010) Allergies, obesity, other risk factors and survival from pancreatic cancer. Int J Cancer 127(10):2412–2419

22. Fearon KC, Baracos VE (2010) Cachexia in pancreatic cancer: new treatment options and measures of success. HPB 12(5):323–324

23. De González AB, Spencer EA, Bueno-de-Mesquita HB, Roddam A, Stolzenberg-Solomon R, Halkjær J et al (2006) Anthropometry, physical activity, and the risk of pancreatic cancer in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev 15(5):879–885

24. van Geenen E-JM, Smits MM, Schreuder TC, van der Peet DL, Bloemena E, Mulder CJ (2010) Nonalcoholic fatty liver disease is related to nonalcoholic fatty pancreas disease. Pancreas 39(8):1185–1190

25. Miele L, Gasbarrini G, Giorgio V, Gasbarrini A, Grieco A (2016) Nonalcoholic fatty liver disease as trigger of cardiovascular and metabolic complication in metabolic syndrome. Intern Emerg Med 11(1):3–10

26. Pollak M (2008) Insulin, insulin-like growth factors and neoplasia. Best Pract Res Clin Endocrinol Metab 22(4):625–638

27. Yu H, Rohan T (2000) Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 92(18):1472–1489

28. Yao Z, Okabayashi Y, Yutsudo Y, Kitamura T, Ogawa W, Kasuga M (2002) Role of Akt in growth and survival of PANC-1 pancreatic cancer cells. Pancreas 24(1):42–46

29. Bergmann U, Funatomi H, Yokoyama M, Beger HG, Korc M (1995) Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles. Cancer Res 55(10):2007–2011

30. Liu W, Bloom DA, Cance WG, Kurenova EV, Golubovskaya VM, Hochwald SN (2008) FAK and IGF-IR interact to provide survival signals in human pancreatic adenocarcinoma cells. Carcinogenesis 29(6):1096–1107

31. Tomizawa M, Shinozaki F, Sugiyama T, Yamamoto S, Sueishi M, Yoshida T (2010) Insulin-like growth factor-I receptor in proliferation and motility of pancreatic cancer. World J Gastroenterol 16(15):1854–1858

32. Muniraj T, Chari ST (2012) Diabetes and pancreatic cancer. Minerva Gastroenterol Dietol 58(4):331

33. Li D (2012) Diabetes and pancreatic cancer. Mol Carcinog 51(1):64–74

34. Salpea KD, Humphries SE (2010) Telomere length in atherosclerosis and diabetes. Atherosclerosis 209(1):35–38

35. Stoeltzing O, Liu W, Reinmuth N, Fan F, Parikh AA, Bucana CD et al (2003) Regulation of hypoxia-inducible factor-1α, vascular endothelial growth factor, and angiogenesis by an insulin-like growth factor-I receptor autocrine loop in human pancreatic cancer. Am J Pathol 163(3):1001–1011

36. Zeng H, Datta K, Neid M, Li J, Parangi S, Mukhopadhyay D (2003) Requirement of different signaling pathways mediated by insulin-like growth factor-I receptor for proliferation, invasion, and VPF/VEGF expression in a pancreatic carcinoma cell line. Biochem Biophys Res Commun 302(1):46–55

37. Stolzenberg-Solomon RZ, Graubard BI, Chari S, Limburg P, Taylor PR, Virtamo J et al (2005) Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers. JAMA 294(22):2872–2878

38. Iodice S, Gandini S, Maisonneuve P, Lowenfels AB (2008) Tobacco and the risk of pancreatic cancer: a review and meta-analysis. Langenbecks Arch Surg 393(4):535–545

39. Nakamura K, Nagata C, Wada K, Tamai Y, Tsuji M, Takatsuka N et al (2011) Cigarette smoking and other lifestyle factors in relation to the risk of pancreatic cancer death: a prospective cohort study in Japan. Jpn J Clin Oncol 41(2):225–231

40. Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar H-J (2004) The risk of cancer in users of statins. J Clin Oncol 22(12):2388–2394

41. Blais L, Desgagné A, LeLorier J (2000) 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med 160(15):2363–2368

42. Simon MS, Desai P, Wallace R, Wu C, Howard BV, Martin LW et al (2016) Prospective analysis of association between statins and pancreatic cancer risk in the Women’s Health Initiative. Cancer Causes Control 27(3):415–423

43. Shimoyama S (2011) Statins are logical candidates for overcoming limitations of targeting therapies on malignancy: their potential application to gastrointestinal cancers. Cancer Chemother Pharmacol 67(4):729–739

44. Thun MJ, Jacobs EJ, Patrono C (2012) The role of aspirin in cancer prevention. Nat Rev Clin Oncol 9(5):259–267

45. Molina MA, Sitja-Arnau M, Lemoine MG, Frazier ML, Sinicrope FA (1999) Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res 59(17):4356–4362

46. Jacobs EJ, Connell CJ, Rodriguez C, Patel AV, Calle EE, Thun MJ (2004) Aspirin use and pancreatic cancer mortality in a large United States cohort. J Natl Cancer Inst 96(7):524–528